National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel

Israel Medical Association Journal

Volumn 13, Issue 3, 2011, Pages 141-146

  Waisbourd, Michael ^a   Goldstein, Michaella ^a   Loewenstein, Anat ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti vascular endothelial growth factor; Bevacizumab; Guidelines; National survey; Ranibizumab

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ARTICLE; CONSENSUS; DRUG USE; FOLLOW UP; HUMAN; ISRAEL; MEDICAL PRACTICE; PATIENT CARE PLANNING; PRACTICE GUIDELINE; QUESTIONNAIRE; SOCIAL STATUS; SUBRETINAL FLUID;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; HEALTH CARE SURVEYS; HUMANS; INTRAVITREAL INJECTIONS; ISRAEL; PHYSICIAN'S PRACTICE PATTERNS; RETINAL DISEASES; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79954554344     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Waisbourd M, Leibovitch I, Loewenstein A, Yassur Y. Lucentis versus Avastin - is there a light at the end of the tunnel for age-related macular degeneration patients? Harefuah 2008; 147 (7): 605-606, 62 (Hebrew).
2. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007; 24 (8): 643-662.
3. Mittra R, Pollack J. Preferences and Trends Membership Survey. American Society of Retinal Specialists 2008:1-11.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfn for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432-1444.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419-1431.
6. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148 (1): 43-58 e1.
7. Tennant MT, Borrillo JL, Regillo CD. Management of submacular hemorrhage. Ophthalmol Clin North Am 2002; 15 (4): 445-452, vi.
8. Haupert CL, McCuen BW, Jafe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fuid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001; 131 (2): 208-215.
9. Laser photocoagulation for neovascular lesions nasal to the fovea. Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes. Macular Photocoagulation Study Group. Arch Ophthalmol 1995; 113 (1): 56-61.
10. Mahajan VB, Elkins KA, Russell SR, et al. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina 2011; 31 (1): 31-35.
11. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008; 28 (10): 1395-1399.
12. Anijeet DR, Hanson RJ, Bhagey J, Bates RA. National survey of the technique of intravitreal triamcinolone injection in the United Kingdom. Eye (Lond) 2007; 21 (4): 480-486.
13. Bhavsar AR, Googe JM, Stockdale CR, et al. Risk of endophthalmitis afer intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009; 127 (12): 1581-1583.
14. Te Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting 2010, Fort Lauderdale, Florida, USA.Note.
15. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) fndings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88 (7): 583-600.
16. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009; 29 (4): 516-522.
17. Waisbourd M, Loewenstein A. Te use of anti angiogenic drugs for central retinal vein occlusion. Harefuah 2010; 149 (4): 243-244 (Hebrew).
18. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Te Central Vein Occlusion Study Group N report. Ophthalmology 1995; 102 (10): 1434-1444.
19. Brown DM. A Study of the efcacy and safety of ranibizumab injection in patients with macular edema secondary to central retinal vein occlusion (CRUISE). Presented at the 27th Annual Meeting of the ASRS, 2009.
20. Argon laser photocoagulation for macular edema in branch vein occlusion. Te Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98 (3): 271-282.
21. Campochiaro PA. A Study of the efcacy and safety of ranibizumab injection in patients with macular edema secondary to Branch Retinal Vein Occlusion (BRAVO). Presented at the 27th Annual Meeting of the ASRS, 2009.